Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit

New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation

SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® NGS Library Prep kit for Plasmid Sequencing. This NGS Library Prep kit enables on-demand and automated library preparation of plasmid DNA for use in next-generation sequencing applications.

Leveraging this new automation capability of the BioXp® platform is expected to enable researchers in high-throughput discovery workflows to reduce hands-on time, cost, and steps of NGS Library Preparation, both accelerating their time to answer and reducing barriers to access to Next-Generation Sequencing.

“This kit represents a major milestone in the evolution of the BioXp® System as it now provides customers with a complete solution in many synthetic biology and genomics workflows. Throughout 2023 we plan to continue to expand capabilities for NGS Library Preparation as well as for DNA and mRNA synthesis beginning from the customer’s sequence, linear DNA, or plasmid DNA. We believe that this transformation of the BioXp platform to an automated molecular biology workstation, will empower researchers with an integrated workflow solution to streamline synthetic biology and multiomic applications throughout discovery. Thus, creating efficiencies in and accelerating their overall discovery process,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.

“In our work manufacturing plasmid DNA for vaccine, gene therapy, or other R&D applications, it is critical to confirm the quality of our end product through DNA sequencing, but the commonly employed sample preparation methods are time consuming and labor intensive. We are pleased to be an Early Access partner with Telesis Bio as we believe their vision for the BioXp platform can help further accelerate and streamline our workflow,” said Santhosh Kallivalappil, Co-founder & Executive Director R&D of Novel Biotechnologies Inc.

For more information on BioXp® NGS Library Prep Kits please visit: telesisbio.com/products/bioxp-kits/ngs/

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® systems consolidate, automate, and optimize the entire synthesis, cloning and amplification workflow. As a result, they deliver virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

About Novel Biotechnology Inc.

Novel Biotechnology Inc. is on a mission to develop disruptive platforms that address unmet needs in the life sciences and pharmaceutical domains. Their focus is on developing new solutions for manufacturing plasmid DNA, a critical starting material for gene therapy, cell engineering, mRNA therapy and vaccine applications. They are developing a platform that is safe, scalable, adaptable to different plasmid backbones and payloads, has improved product quality, and is many times more productive than existing systems. Through their services business, they are currently offering plasmid DNA manufacturing services to a growing base of customers.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

GlobeNewswire Distribution ID 8842032

CertiK Redefines Security in Crypto Through Integration of Security Score With CoinMarketCap

  • CertiK is the leading smart contract audit and Web3 security company, with approximately 70% market share of the top 500 CoinMarketCap audited projects.
  • The integration of CertiK’s Trust Score into CoinMarketCap is a leap forward for security and transparency across the Web3 industry.

New York, New York, May 18, 2023 (GLOBE NEWSWIRE) — CertiK, Web3’s leading security firm, is proud to announce the integration of its Security Score into CoinMarketCap, the most widely-used platform for ranking and discovering cryptocurrencies.

The CertiK Security Score ranks projects against a comprehensive set of security metrics, enabling users to easily assess the security of a project at a glance. By assessing factors such as smart contract code, code audits, and the developer team’s background, the Security Score is a powerful addition to the diligent investor’s toolkit.

Since its launch in 2013, CoinMarketCap has established itself as the leading platform for tracking the prices, market capitalization, trading volumes, and other statistics of cryptocurrencies. CoinMarketCap is the first port of call for many entrants to the crypto world, and with its ever expanding suite of educational and technical resources it remains an indispensable tool for all users and investors. CertiK has audited over 70% of the top 500 Web3 projects as ranked by CoinMarketCap.

“With more than $3.7 billion of value drained from Web3 platforms and users in 2022, inadequate security remains an existential threat to the industry,” said CertiK co-founder Prof. Ronghui Gu. “By putting security front and center with this integration of the Security Score, CertiK and CoinMarketCap are joining forces to bring transparency and trust around web3 projects.. Projects that take security seriously can use their Security Score as proof of the fact.””

Users and investors now have a powerful tool at their disposal to help them evaluate the security of Web3 projects. The due diligence process should be as comprehensive as possible, and the integration of CertiK’s Security Score into CoinMarketCap makes it easy to identify projects that understand the importance of security for the future of their project and their community.

CertiK is on a mission to raise the standard of security and transparency in Web3, and this partnership with CoinMarketCap is a major step toward a safer, more open ecosystem.

About CertiK
CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology and expert manual review to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK secures the Web3 world, by applying cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

www.certik.com

About CoinMarketCap

CoinMarketCap is the world’s most-referenced price-tracking website for crypto assets in the rapidly growing cryptocurrency space. Its mission is to make crypto discoverable and efficient globally by empowering retail users with unbiased, high quality and accurate information for drawing their own informed conclusions.

www.coinmarketcap.com

Media Contact:
Reannah Smith
reannah@lunapr.io

GlobeNewswire Distribution ID 1000810776

Impulse Dynamics Announces First Implant for CCM-D™ Clinical Trial

World’s First Device Combining CCM Therapy With an ICD in a Single Rechargeable Implant That Treats Both Heart Failure Symptoms and Sudden Cardiac Death

MARLTON, N.J., May 18, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced the completion of the first implantation for the INTEGRA-D clinical trial, designed to evaluate the safety and efficacy of two proven cardiac therapies combined — CCM® and an implantable cardioverter defibrillator (ICD) — in a single device (CCM-D). The Optimizer® IntegraTM CCM-D System delivers CCM therapy to improve quality of life and reduce heart failure symptoms, and ICD therapy to treat life-threatening arrhythmias that may cause sudden cardiac death. The investigational technology is rechargeable with long battery life, potentially reducing the need for replacement procedures.

The journey of a heart failure patient often involves debilitating symptoms and declining quality of life.

CCM therapy delivered by the Optimizer System improves quality of life and helps patients feel better. Patients indicated for CCM therapy may also be at a higher risk for arrythmias and sudden cardiac arrest and are therefore often offered an ICD to treat their heart for life-threatening arrythmias, should they occur. The INTEGRA-D trial is the first to evaluate the Optimizer Integra CCM-D System that combines both therapies into a single device, designed to last for many years.

“The first-in-the-world implant of this novel technology has potential to advance treatments for patients living with heart failure,” said Niraj Varma, M.D., Ph.D., electrophysiologist at Cleveland Clinic and National Primary Investigator of the INTEGRA-D clinical trial. “The trial aims to study whether this device can protect heart failure patients from the risk of sudden cardiac death while also treating heart failure symptoms.”

“We hope combining cardiac contractility modulation therapy and ICD therapy with prolonged battery life will reduce the number of leads and the number of procedures a patient may have to endure,” said Bruce Wilkoff, M.D., Director of Cardiac Pacing and Tachyarrhythmia Devices at Cleveland Clinic and Principal Investigator of the INTEGRA-D trial. “The first implant went well, and we look forward to further studying this device.”

The INTEGRA-D trial is a multicenter study of 300 subjects from 75 centers that will evaluate the combination of CCM and ICD therapy in a single device via the Optimizer Integra CCM-D System. The study will assess the performance of the CCM-D device in effectively treating episodes of ventricular tachycardia and/or ventricular fibrillation while also providing CCM treatment for heart failure. Patients enrolled in the study will receive the Optimizer Integra CCM-D System, and will be followed for at least two years.

“This clinical study is important in proving the potential benefit of combining CCM therapy, which improves quality of life in patients with heart failure, with gold-standard ICD technology that delivers lifesaving therapy for sudden cardiac death,” said Nir Uriel, M.D., Director of Advanced Heart Failure and Cardiac Transplantation at New York-Presbyterian and National Co-Principal Investigator for the INTEGRA-D trial. Dr. Uriel is also a professor of cardiology at Columbia University Vagelos College of Physicians and Surgeons and an Adjunct Professor of Medicine in the Greenberg Division of Cardiology at Weill Cornell Medicine.

“Today’s announcement is another example of our commitment to a continuous pace of innovation to build a comprehensive platform in interventional heart failure and help improve the lives of many patients that suffer from this debilitating disease,” said Simos Kedikoglou, M.D., Chief Executive Officer of Impulse Dynamics. “We are proud to partner with physicians at leading centers around the world to conduct important research on this first-of-its-kind rechargeable combination device designed to address a major unmet need of a large patient group.”

About the Optimizer Integra CCM-D System and CCM Therapy

The Optimizer Integra CCM-D System is an investigational device that combines CCM therapy and ICD therapy into one device. “Investigational” means that the study device is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA).

Impulse Dynamics currently offers the Optimizer system that is FDA-approved and CE-marked. The Optimizer system delivers CCM therapy — the company’s proprietary technology — to the heart. CCM therapy has been designed by Impulse Dynamics to significantly improve the heart’s contraction, allowing more oxygen-rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM is the brand name for cardiac contractility modulation — a therapy that delivers non-excitatory electrical pulses from the implantable Optimizer device to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer-reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedInTwitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM-D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Integra CCM-D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Rohan More, Global Vice President of Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

Harriss Currie, Chief Financial Officer
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

GlobeNewswire Distribution ID 8841961

Architects Lina Ghotmeh and Asif Khan appointed for two major museums in AlUla, Saudi Arabia

Lina Ghotmeh and Asif Khan, courtesy Royal Commission for AlUla, photo by Luke Walker

Architects Lina Ghotmeh and Asif Khan appointed for two major museums in AlUla, Saudi Arabia

ALULA, Saudi Arabia, May 18, 2023 (GLOBE NEWSWIRE) — The Royal Commission for AlUla (RCU) announces Lina Ghotmeh and Asif Khan as architects for two upcoming museums in its constellation of cultural assets. Ghotmeh will design the contemporary art museum and Khan will design the museum of the Incense Road. Both museums are situated in AlUla, a destination in northwest Arabia with 7,000 years of continuous human history.

Khan, who was awarded a MBE for his services to architecture and is currently working on the renewal of the Barbican Centre and the new London Museum, is known for his radical approach to architecture, which merges history with the future, grounding projects in material experimentation and social context.

Award winning Ghotmeh, who is designing the 2023 Serpentine Pavilion, creates work that sits at the intersection of art, architecture and design. Her practice is developed through a process of thorough historical research, emerging in complete symbiosis with nature as exquisite interventions that enliven memories and the senses.

The architects were chosen through an international competition. The jury comprised of key stakeholders and specialists in architecture, landscape and museology, supported by a technical panel, and was chaired by Dr Khaled Azzam, the architect of AlUla’s Journey Through Time Masterplan.

We are excited to announce the appointed architects to these two significant museums – the first of 15 cultural assets being developed as part of AlUla’s Journey Through Time Masterplan. AlUla is a spectacular landscape of discovery, where heritage, works of nature and humankind combine to reveal a long and intimate relationship between people and their environment. This Masterplan will guide the reinvigoration of AlUla establishing a new cultural legacy including the implementation of a circular economy expected to create 38,000 new jobs.

Dr Khaled Azzam – Architect, Journey Through Time Masterplan, Royal Commission for AlUla

The architecture of the contemporary art museum in AlUla immerses visitors in a creative journey from the desert expanse to the lush cultural oasis of AlUla, interweaving the natural environment, agriculture and art to reveal the heart of contemporary culture. Through a series of garden pavilions, the museum presents a constant interplay between art and nature, capturing the essence of this unique place. The galleries offer surprising and anchored perspectives on the many facets of AlUla, from the microclimates of the oasis to the expanse of the desert, evoking a deep sense of attachment to the land and its heritage.

Lina Ghotmeh, architect, contemporary art museum in AlUla

AlUla resonated with me deeply as did the local community members I met. The design takes the form of a public space, not a museum within walls, situated in AlJadidah village with galleries and spaces for sensory experiences and learning. The mountains are a constant background, whose sand dunes reach down to greet the edges of the museum, while stepped terraces of gardens act as a new interface between the village and the oasis. 

I am excited about how the museum of the Incense Road can be brought into the collective memory of the world, and become a transformative asset for the local community.

Asif Khan, architect, museum of the Incense Road

The contemporary art museum in AlUla is a museum of regional and global contemporary art with Arabia at its heart. Offering a core collection of works by artists from regions adjoining the Red Sea, the Arabian Sea and the Eastern Mediterranean in dialogue with their contemporaries from across the world, the collection aims to evolve in partnership with these artists, including a robust programme of commissioned works. As the primary art museum in AlUla, it contributes to the region’s legacy as a cultural beacon, generating opportunities for artists, designers, creatives and curators.

An adjoining series of artist-designed gardens will ensure the experience is connected to the landscape in which it sits. Integrated into the distinctive AlUla oasis, set amongst vegetable gardens, palm groves, mountain ranges and an ancient settlement, the museum will explore sensitive environmental design and function as a catalyst for environmental renewal and regeneration of the oasis. It will be structured as an archipelago of pavilion galleries interspersed with a mosaic of artist gardens. Its balance of interior and exterior galleries and gardens will allow visitors to define their own encounters both with art and the natural landscape.

The museum of the Incense Road will be the world’s first museum dedicated to this epic and millennia-old network of major land and sea trading routes, celebrating AlUla’s cultural legacy as a place of exchange at the confluence of civilisations. Bringing to life global histories, through which ideas, goods and culture were exchanged, it shines a light on north-west Arabia as a cultural epicentre. Living and dynamic narratives will include spotlighting the discoveries of ongoing excavations, highlighting the active nature of AlUla’s archaeological sites and the cultural importance of the Incense Road. At the forefront of innovative museum practice, it will enable visitors to engage through layered, multidisciplinary interpretation anchored by carefully curated collections.

The museum of the Incense Road is being developed in dialogue with AlUla’s ancient heritage – including Hegra, Saudi Arabia’s first UNESCO World Heritage Site – and its host village, AlJadidah. It will be an extension of the urban fabric that sits towards the oasis edge, looking out on a vista where Dadan and Hegra – once vibrant cities that thrived as a result of the Incense Road – are located. Guided by subject experts and the local community, the museum of the Incense Road will continue to be developed through extensive local and international collaboration with specialists across fields including academia and museology.

Both museums offer a unique entry point into AlUla’s rich and extensive cultural offering and will be developed with a socially responsible approach to the preservation, interpretation, meaningful community engagement and presentation of AlUla’s cultural inheritance. They will consider how to reduce environmental impact while building meaningful spaces, particularly regarding conservation, controlled temperature, humidity and lighting, and will work with a network of cultural leaders at an institutional, thematic and discipline level in the spirit of reciprocal exchange.

Notes to editors

About AlUla:

Located 1,100 km from Riyadh, in north-west Saudi Arabia, AlUla is a place of extraordinary natural and human heritage. The vast area, covering 22,561km², includes a lush oasis valley, towering sandstone mountains and ancient cultural heritage sites dating back thousands of years to when the Lihyan and Nabataean kingdoms reigned.

The most well-known and recognised site in AlUla is Hegra, Saudi Arabia’s first UNESCO World Heritage Site. A 52-hectare ancient city, Hegra was the principal southern city of the Nabataean Kingdom and comprises more than 100 well-preserved tombs with elaborate facades cut out of the sandstone outcrops surrounding the walled urban settlement. Current research also suggests Hegra was the most southern outpost of the Roman Empire after the Nabataeans were conquered in 106 CE.

In addition to Hegra, AlUla is home to fascinating historical and archaeological sites such as Ancient Dadan, the capital of the Dadan and Lihyan Kingdoms, which is considered one of the most developed 1st-millennium BCE cities of the Arabian Peninsula; thousands of ancient rock art sites and inscriptions at Jabal Ikmah; and AlUla Old Town, a labyrinth of more than 900 mudbrick homes developed from at least the 12th century.

About The Royal Commission for AlUla:

The Royal Commission for AlUla (RCU) was established by royal decree in July 2017 to protect and safeguard AlUla, a region of outstanding natural and cultural significance in north-west Saudi Arabia. RCU is embarking on a long-term plan to develop and deliver a sensitive, sustainable transformation of the region, reaffirming it as one of the country’s most important archaeological and cultural destinations and preparing it to welcome visitors from around the world. RCU’s development work in AlUla encompasses a broad range of initiatives across archaeology, tourism, culture, education and the arts, reflecting the ambitious commitment to cultivate tourism and leisure in Saudi Arabia, outlined in Vision 2030.

Lina Ghotmeh works and lives in Paris, where she leads her multidisciplinary practice Lina Ghotmeh — Architecture. Her visionary and materially sensitive works emerge in complete symbiosis with their environment while soliciting memory and senses.

Lina Ghotmeh is the nominated Architect for this year’s 22nd Serpentine Pavilion and her projects include Ateliers Hermès (first low carbon, energy positive building in France) delivered this April 2023, Stone Garden crafted tower and gallery spaces in Beirut (Dezeen Architecture of the year 2021 Prize), the Estonian National Museum (Grand Prix Afex 2016, project she designed in partnership with Dorell.Ghotmeh.Tane), Wonderlab Master crafts exhibition in Tokyo and Beijing & award winning Les Grands Verres restaurants for the Palais de Tokyo, Paris, France.

She is the recipient of multiple awards including the 2020 Schelling Prize, the 2020 Tamayouz “Woman of Outstanding Achievement”, the French Fine Arts Academy Cardin Award 2019, the Architecture Academy Dejean 2016 and the French Ministry AJAP Prize in 2008. Her works have been exhibited at the 17th Architecture Biennale in Venice, at the MAXXI in Rome, and currently at the Cooper Hewitt in New York.  She is active in Academic life and was Louis I Khan professor at Yale and Gehry Chair at the University of Toronto.

Asif Khan founded his London-based practice in 2007, which designs buildings, landscapes, installations, exhibitions and objects. His work is concerned with sensory experience, craftsmanship, cultural exchange and the merging of history with future worlds.

Asif Khan is currently working on the Barbican Art Centre Renewal, the new London Museum, opening 2026, itself the largest cultural project in Europe, and Liverpool Canning Dock waterfront transformation, a site at the centre of the Transatlantic Slave Trade. In 2020 he completed 6.5km of public realm design of Dubai Expo 2020, where his carbon-fibre Entry Portals received the Dezeen public award 2021 and nomination for the Aga Khan award for Architecture. He received the Grand Prix for Innovation (Cannes 2014) and Architect of the Year (German Design Council 2017).

His works have been exhibited at the Royal Academy of Arts, V&A, Milan Salone, Milan Triennale, Gwangju Design Biennale, the Design Museum, London, London Design Week, Tokyo Design Week, and currently at MAAT Lisbon. He has taught at the Royal College of Art and at Musashino Art University, Tokyo. Khan was awarded an MBE for Services to Architecture in 2017 and currently serves as Vice Chairman of the Design Museum in London.

Press contacts:

Vicky Newark
Pelham Communications
vicky@pelhamcommunications.com

Sherif Elhalafawy
Royal Commission for AlUla
s.elhalafawy@rcu.gov.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e9648d36-fa73-489c-938c-7bb1d439c81e

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

A video accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/725cb185-c4e4-4e48-a341-ee572ff27b60

GlobeNewswire Distribution ID 8842227

Kiplin Metals Submits Exploration Permits for the Cluff Lake Road (“CLR”) Uranium Project in Saskatchewan

Satellite Image of Kiplin Mine

The CLR Project is 5 km east of the Cluff Lake Road (Hwy 955), which leads to the historic Cluff Lake Mine, which historically produced approximately 62,000,000 lbs of yellowcake uranium.

VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) — Kiplin Metals Inc. (TSX-V: KIP) (the “Company” or “Kiplin“) announces the submission of exploration permits for its upcoming summer exploration program at its key Cluff Lake Road (CLR) uranium project. The permits are currently under review by the Saskatchewan Ministry of Environment for approval.

The CLR property is situated adjacent to F3 Uranium Corp.’s (“F3”) (previously known as Fission 3.0) prominent Paterson Lake North (PLN) project. In November 2022, F3 uncovered the JR high-grade uranium zone, which recently reported intersections (refer to F3 press release dated February 6, 2023) in drill hole PLN22-038 of 11.0 meters averaging 4.20% triuranium octoxide, including a high-grade 4.5-meter interval averaging 9.8% U3O8. The JR uranium zone represents the newest basement-hosted uranium deposit in the Athabasca, similar to the Triple R uranium deposit owned by Fission Uranium Corp.

Kiplin’s summer program, contracted to Grander Exploration, will involve geophysical surveying focused on the central part of the property. The survey will target multiple prospective areas already identified within the CLR property, including:

  • Three parallel (South-Southeast) conductors spanning a width of one kilometre on F3’s PLN property, referred to as the North Conductor Complex, which extend onto the western part of the CLR property.
  • Several other magnetic lineaments within the CLR property, both parallel and intersecting the North Conductor Complex trend.
  • Multiple Alpha Track radon gas sensor anomalies previously completed (2017) and spectrometer radioactivity anomalies detected by the Company in 2022 (refer to Press Release, November 23, 2022). Background radioactivity readings obtained using a handheld Radiation Solutions RS-125 Super-SPEC gamma-ray spectrometer (*) range between 20-50 counts per second (cps), with over 100 anomalous boulders in the 100-500 cps range identified.

(*) The spectrometer readings provided in this news release were obtained using a handheld Radiation Solutions RS-125 Super-SPEC gamma-ray spectrometer, measuring in counts per second. It is important to note that spectrometer readings are not directly or uniformly correlated to uranium grades of the measured rock sample and should be considered as an initial indication of radioactive material presence only.

The Company believes that the CLR property’s combination of multiple EM (electromagnetic) conductors, magnetic lineaments, radon gas, and radioactivity anomalies make it a highly prospective location for discovering a basement-hosted uranium deposit.

Kiplin intends to conduct its exploration activities in compliance with the strictest environmental management standards and maintain open communication with local stakeholders, including indigenous communities, throughout the permitting, exploration, and closure phases.

The Company will share updates on the progress of its permit approval and work program as information becomes available. Kiplin emphasizes that findings and observations on neighbouring properties do not guarantee the presence of similar mineralization or geological features on their properties.

Dr. Peter Born, PGeo, the designated qualified person as defined by National Instrument 43-101, is responsible for and has approved the technical information contained in this release.

About Kiplin Metals Inc.
Kiplin Metals Inc. is a mineral exploration firm dedicated to identifying and developing high-potential mineral exploration opportunities. By advancing our projects from discovery through production, we strive to create significant value for our shareholders. This comprehensive approach enables Kiplin Metals to generate outstanding shareholder returns throughout the entire mining process. This vertically integrated strategy allows Kiplin Metals to achieve exceptional shareholder value through the entire life-cycle of the mining process.

Cluff Lake Road Uranium Project. Kiplin Metals has the right to earn a one-hundred percent interest in the Cluff Lake Road Uranium Project (referred to as the “CLR Project“). The CLR Project spans approximately 531 hectares in the southwestern region of the Athabasca Basin in northern Saskatchewan, an area known for recent discoveries, including the Arrow and Triple R Uranium deposits. The CLR Project is situated 5 km east of Cluff Lake Road (Highway 955), which connects to the historic Cluff Lake Mine, a site that has produced an estimated 62,000,000 lbs of yellowcake uranium in the past.

Kiplin Mine

For further information, contact the Company at info@kiplinmetals.com, or visit the Company’s website at www.kiplinmetals.com.

On behalf of the Board,

Kiplin Metals Inc.

For further information, contact the Company at 604-622-1199.

On behalf of the Board of Directors,

“Peter Born”
Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Contact Data

CONTACT:

MRKT360 INC

https://mrkt360.com

Alex Zertuche

alexz@mrkt360.com

For E.S.T Office Hours, Call 1 416-477-0587

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7aefb29d-d090-4246-b59f-d3bc29e55a16

GlobeNewswire Distribution ID 8841971